Intermittent Dosing Schedule for Zandelisib Appears Safe With Low Incidence of High-Grade AEs in R/R B-Cell MalignanciesJuly 30th 2022
Patients with relapsed/refractory B-cell malignancies who received zandelisib at 60 mg via an intermittent dosing schedule experienced a low incidence of grade 3 or higher adverse effects.
Phase 2 Alliance A059102 Trial Will Assess the Efficacy of Duvelisib/Azacitidine Plus CHOP/CHOEP for Peripheral T-Cell LymphomaJuly 1st 2022
In the phase 2 Alliance A059102 trial, patients with treatment-naïve CD30-negative peripheral T-cell lymphoma will be treated with duvelisib and azacitidine plus CHOP/CHOEP chemotherapy.
Comprehensive Geriatric Assessment May Predict Survival Based on Frailty in Hematologic MalignanciesJune 2nd 2022
Investigators indicated that comprehensive geriatric assessment could be used to determine whether older, frail patients with hematologic cancers can undergo intensive treatment with chemotherapy and whether curative treatment is viable.
Qualitative Analysis Shows Peer Support May Offer Benefit to Those Undergoing Allogeneic HSCTJune 1st 2022
Semi-structured qualitative interviews revealed that patients undergoing allogeneic hematopoietic stem cell transplant could benefit from peer support prior to and during transplantation.
Alina Markova, MD, on the Future of Topical Ruxolitinib in Cutaneous Chronic GVHD and Multidisciplinary ImplicationsMay 28th 2022
Alina Markova, MD, speaks about future research efforts for topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease, and multidisciplinary implications of current research.
Recap: Earlier Detection May Be Key to Treatment Advances in Chronic GVHDMay 25th 2022
An expert in hematology/oncology, Dr Yi-Bin Chen, provides insight on chronic GvHD, with a focus on early detection of disease and therapeutic options for the management of steroid-refractory chronic GvHD.
Perspectives on COVID-19 Prophylaxis and VaccinationMay 19th 2022
To close the discussion, panelists reflect on their practices’ guidance on long-acting antibody prophylaxis and vaccination against COVID-19 for patients with graft-versus-host-disease (GVHD).
Geriatric Consultation Did Not Significantly Improve Survival in Hematologic Malignancies But Increased End of Life Care DiscussionsMay 17th 2022
Geriatric consultations vs standard of care for patients with hematologic malignancies who were pre-frail or frail did not significantly improve survival at 1 year but did increase discussions on end-of-life goals of care.
Alina Markova, MD, on the Rationale for Assessing Topical Ruxolitinib in Cutaneous Chronic GVHDMay 13th 2022
Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Treatment Approaches Using Ruxolitinib in GVHDMay 12th 2022
In a discussion on the use of ruxolitinib in GVHD, experts consider the potential role of dose reductions or dose holds to mitigate toxicity and comment on experiences with combining or sequencing therapies in later lines of treatment.
Additional Approaches for Steroid-Refractory Chronic GVHDMay 12th 2022
Expert panelists comment on additional treatment options for significant steroid-refractory chronic GVHD following initial therapeutic intervention, including rechallenging with prophylactic agents or initiating B-cell therapy.
Dearth of Participation From Black Patients Noted in CAR T Clinical Trials Supporting FDA ApprovalsMay 9th 2022
Investigators identified that in pivotal clinical trials supporting FDA approvals of CAR T-cell therapies for patients with hematologic cancer, Black patients were significantly underrepresented.
The Role of Photopheresis for GVHD Following ProgressionMay 5th 2022
A panel of experts shares key insights into the role of photopheresis when patients with GVHD progress following initial treatment and emphasize its potential for patients with high skin involvement.
Clinical Scenario 2: Steroid-Refractory Chronic GVHDMay 5th 2022
Key opinion leaders in stem cell transplant and cellular immunotherapy review therapeutic considerations for the clinical scenario of a patient with steroid-refractory chronic GVHD.
Enrollment Low for Black Patients With Hematologic Malignancies On Trials Supporting FDA Approvals of CAR T-Cell TherapyApril 28th 2022
Investigators observed low enrollment of Black patients on CAR T-cell therapy clinical trials that supported FDA decisions in hematologic malignancies, especially in multiple myeloma.
The Effect of Trial Design on Approval of GVHD TherapiesApril 28th 2022
Panelists consider the importance of studying trial drugs in a blinded, randomized fashion to mitigate physician and patient bias regarding patient-reported outcomes for GVHD therapies.
Clinical Scenario 1: First- and Second-Line Treatment for GVHDApril 28th 2022
John F. DiPersio, MD, PhD, presents the clinical scenario of a 71-year-old patient postmatched unrelated donor HSCT, and the panel discusses first- and second-line treatment approaches including topical and systemic therapies.
Total Body Irradiation Plus Prophylactic PTCy, Tac, and MMF Yields Low cGVHD Incidence in Hematologic CancerApril 27th 2022
Patients with hematologic cancer experienced a low incidence of chronic graft-versus-host disease after receiving a regimen consisting of myeloablative hematopoietic cell transplantation and total body irradiation plus prophylactic post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.
Prophylactic Belimumab Could Prevent Chronic GVHD Following Allogenic TransplantationApril 24th 2022
Findings from a phase 1 study indicate that belimumab could be a safe prophylactic option to prevent chronic graft-versus-host disease in adult patients undergoing allogenic transplant.
Investigators Identify New Gene Signature Linked With Response to Topical Ruxolitinib for Cutaneous Chronic GVHDApril 24th 2022
Findings from a phase 2 clinical trial identified a differentially expressed gene profile in those diagnosed with nonsclerotic and superficially sclerotic chronic graft-vs-host-disease who responded to topical ruxolitinib.